Concentration of Management Resources on Three Businesses
First written in FY2016. 20 of 27 entries say "Restated". Latest entry: FY2025-H1.
57 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
Under Long-Term Management Vision 2025 and Medium-Term Management Plan 2025, the Group continued its policy of becoming a global platform company through the Reagents and Instruments Business and CDMO Business. - FY2024RestatedAnnual report
「The Group formulated Long-Term Management Concept 2025 in 2020 and has been implementing it. In May 2023, it also formulated Medium-Term Management Plan 2025, a specific three-year execution plan for the latter half of Long-Term Management Concept 2025.」
Continues the policy of promoting the business through the Reagents and Instruments business and CDMO business under Long-Term Management Concept 2025 and Medium-Term Management Plan 2025. - FY2024-Q3RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
Under Long-Term Management Vision 2025 and Medium-Term Management Plan 2025, the Group continued its overall policy of becoming a global platform company through the Reagents and Instruments Business and CDMO Business. - FY2024-Q2RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
Under Long-Term Management Vision 2025 and Medium-Term Management Plan 2025, the Group continued its policy of developing core technologies for drug discovery through the Reagents and Instruments Business and CDMO Business and becoming a global platform company. - FY2024-Q1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2025, ending in fiscal 2025, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and CDMO business, with the aim of becoming a global platform company supporting the infrastructure of the life sciences industry.」
Continues the policy of developing drug-discovery platform technologies through the Reagents and Instruments business and CDMO business and becoming a global platform company under Long-Term Management Concept 2025 and Medium-Term Management Plan 2025. - FY2023ReframedAnnual report
「Under its corporate philosophy of contributing to people’s health through the development of innovative biotechnologies, including gene therapy, the Group is transforming its business structure to achieve rapid growth and overcome the post-COVID performance cliff. Through sustainable growth in the Reagents and Instruments business and rapid growth in the CDMO business, it will develop bio-drug-discovery platform technologies and pursue a business strategy aimed at becoming a global platform company supporting the infrastructure of the life sciences industry.」
The previous policy of business concentration and becoming a drug-discovery company was restructured around post-COVID business transformation, growth in the Reagents and Instruments and CDMO businesses, and becoming a global platform company. - FY2023-Q3RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and CDMO business, with the aim of becoming a drug-discovery company that continuously creates new modalities. It also actively worked to ensure a stable supply of products related to testing for COVID-19 and to establish manufacturing capabilities for regenerative medicine products.」
Continues the policy of becoming a drug-discovery company through the Reagents and Instruments business and CDMO business, while maintaining stable supplies of testing-related products and establishing manufacturing capabilities for regenerative medicine products. - FY2023-Q2RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
The Group continued its overall policy of becoming a drug-discovery company through the Reagents and Instruments Business and CDMO Business under Long-Term Management Vision 2025 and Medium-Term Management Plan 2022. - FY2023-Q1RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
The Group continued its overall policy of becoming a drug-discovery company through the Reagents and Instruments Business and CDMO Business under Long-Term Management Vision 2025 and Medium-Term Management Plan 2022. - FY2022-Q3RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
Continues the overall policy of pursuing drug-discovery operations through the Reagents and Instruments Business and Contract Business under Long-Term Management Vision 2025 and Medium-Term Management Plan 2022. - FY2022-Q2RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
Continues the policy of pursuing drug-discovery operations centered on the Reagents and Instruments Business and Contract Business under Long-Term Management Vision 2025 and Medium-Term Management Plan 2022. - FY2022-Q1RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
Continues the policy of pursuing a drug-discovery company through the Reagents and Instruments business and contract business under Long-Term Management Concept 2025 and Medium-Term Management Plan 2022. - FY2021-Q2RestatedAnnual report
「Against this backdrop, under its corporate philosophy, “We contribute to people’s health through the development of innovative biotechnologies, including gene therapy,” and the newly formulated Long-Term Management Concept 2025 and Medium-Term Management Plan 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Research Reagents and Scientific Instruments business and CDMO business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
Continues the framework of integrating management resources and becoming a drug-discovery company presented in the previous quarter. - FY2021-Q1ReframedAnnual report
「The Group had established business divisions by product and service, with each division formulating comprehensive strategies covering the products and services it handled, including those of subsidiaries, and conducting business activities accordingly. From April 2020, however, it decided to develop bio-drug-discovery platform technologies and pursue the creation of a drug-discovery company generating new modalities by integrating the management resources held by each business division, and accordingly to phase out the business-division system.」
From April 2020, the policy shifted from concentrating resources by business division to integrating the resources of each division and phasing out the business-division system. - FY2020-Q3RestatedAnnual report
「Against this backdrop, the Group continued initiatives aimed at enhancing its presence as both a global company and a regenerative medicine products company and achieving substantial growth, as set out in the overall policy of Takara Bio Medium-Term Management Plan 2019, the final year of which began in the fiscal year ended March 2018.」
In the final year of Medium-Term Management Plan 2019, the Group continued initiatives to promote its business strategy, strengthen its management platform, globalize its operations, and develop as a regenerative medicine products company. - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group continued initiatives aimed at enhancing its presence as both a global company and a regenerative medicine products company and achieving substantial growth, as set out in the overall policy of Takara Bio Medium-Term Management Plan 2019, the final year of which began in the fiscal year ended March 2018.」
The policy of globalization and development as a regenerative medicine products company continued under the medium-term plan after the business portfolio was reorganized around two businesses. - FY2019ReframedAnnual report
「When this medium-term plan was formulated, the Group launched it with the basic policy of promoting strategies for the three business divisions—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and strengthening the management platform supporting them, enhancing its presence as both a global company and a company manufacturing regenerative medicine products, and pursuing rapid growth. During the consolidated fiscal year, however, the Group transferred both businesses comprising the Medical Foods Biotechnology business, health foods and mushrooms, and decided to further sharpen its focus and selectively allocate management resources.」
Following completion of the transfers of the health foods and mushroom businesses, the portfolio was reorganized from a three-business framework to a concentration of management resources centered on two businesses. - FY2019-Q3AdvancedAnnual report
「As described above, to achieve rapid growth across the Group, the Group decided to further sharpen its focus and selectively allocate management resources by transferring the health foods business to Shionogi Healthcare Co., Ltd. and the mushroom business to Yukiguni Maitake Co., Ltd.」
The transfer of the health foods business was completed on 1 January 2019, and a transfer agreement was also signed for the mushroom business, with 1 March 2019 as the scheduled effective date, giving concrete form to the selective concentration of management resources. - FY2019-Q2ReframedAnnual report
「During the six-month period ended 30 September 2018, to achieve rapid growth across the Group, the Group decided to further sharpen its focus and selectively allocate management resources by entering into an absorption-type company split agreement under which the health foods business within the Medical Foods Biotechnology business would be transferred to Shionogi Healthcare Co., Ltd., with 1 January 2019 as the scheduled effective date.」
While maintaining the three-business framework, the Group reorganized its portfolio by transferring the health food business through a company split and further advancing the selective concentration of management resources. - FY2019-Q1RestatedAnnual report
「Under Takara Bio Medium-Term Management Plan 2019, a three-year medium-term management plan launched in the fiscal year ended March 2018, the Group adopted as its overall policy the promotion of strategies for the three business divisions—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—the strengthening of the management platform supporting them, enhancement of its presence as both a global company and a company manufacturing regenerative medicine products, and the pursuit of rapid growth. It pursued initiatives to achieve the upwardly revised operating profit target of ¥6,000 million for the final year.」
Continues the policy of promoting the three business strategies, strengthening the management platform, globalizing the business and becoming a regenerative medicine products company. The upward revision of the final-year operating profit target is recorded in t39. - FY2018-Q3RestatedAnnual report
「Against this backdrop, under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group advanced the strategies for its three business divisions—biotechnology industry support, gene medicine, and medical food biotechnology—and strengthened the management base supporting them. It worked to enhance its presence as both a global company and a company specializing in regenerative medicine products, and pursued initiatives aimed at achieving significant growth.」
Continues to advance the strategies for the three businesses, strengthen the management base, and develop the Group as a global company and a regenerative medicine products company under Medium-Term Management Plan 2019. - FY2018-Q2RestatedAnnual report
「Against this backdrop, under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group advanced the strategies for its three business divisions—biotechnology industry support, gene medicine, and medical food biotechnology—and strengthened the management base supporting them. It worked to enhance its presence as both a global company and a company specializing in regenerative medicine products, and pursued initiatives aimed at achieving significant growth.」
Continues the policy of concentrating management resources on the three businesses while strengthening the management base and pursuing growth under the medium-term management plan. - FY2018-Q1RaisedAnnual report
「Against this backdrop, under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group promoted the strategies for its three business divisions—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and strengthened the management platform supporting them. It worked to enhance its presence as both a global company and a company manufacturing regenerative medicine products, and pursued initiatives aimed at achieving rapid growth.」
While maintaining its focus on the three businesses, the Group broadened the strategy under the three-year plan to include strengthening the management platform, enhancing its presence as a global company and regenerative medicine products company, and achieving rapid growth. - FY2017-Q3RestatedAnnual report
「Against this backdrop, the Group leveraged its biotechnology expertise built over many years, concentrated management resources in three areas—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and worked to improve its performance.」
Continues to concentrate management resources on the three businesses. - FY2017-Q2RestatedAnnual report
「Against this backdrop, the Group leveraged its biotechnology expertise built over many years, concentrated management resources in three areas—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and worked to improve its performance.」
Continues to concentrate management resources on the three businesses. - FY2017-Q1RestatedAnnual report
「Against this backdrop, the Group leveraged its biotechnology expertise built over many years, concentrated management resources in three areas—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and worked to improve its performance.」
Reiterates the concentration of management resources on the three businesses. - FY2016First statedAnnual report
「Against this backdrop, the Group leveraged its biotechnology expertise built over many years, concentrated management resources in three areas—Bioindustry Support, Gene Medicine and Medical Foods Biotechnology—and worked to improve its performance.」
Explicitly identifies the three businesses as the focus of management-resource concentration.